Study to Investigate the Effect of Deferasirox on the Pharmacokinetics of Midazolam

This is a study to investigate the pharmacokinetics of deferasirox

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Healthy

Age range

18 year–45 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Good health
No evidence of iron deficiency
Weight between 50 and 100 kg
Body Mass Index between 19 and 29 kg/m2

Exclusion criteria

Use of certain drugs, herbal remedies or nutrients

Other protocol-defined inclusion/exclusion criteria may apply

Treatment and study plan

Deferasirox

Drug

Primary outcomes

To assess the effect of deferasirox on the pharmacokinetics of midazolam

Secondary outcomes

Safety assessed by adverse events (AEs)

Sponsors and collaborators

Lead sponsor

Novartis

Industry

Registry information

Official study title

An Open-label, One-sequence Cross-over Study to Investigate the Effect of Deferasirox on the Pharmacokinetics of Midazolam in Healthy Volunteers

Important dates

Study start: 2006
First posted: Jan 29, 2007
Registry last updated: Nov 19, 2009

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed